Navigation Links
BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 11th Annual Healthcare Conference
Date:9/3/2009

LYNBROOK, N.Y., Sept. 3 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009, at 12:05pm ET at the New York Palace Hotel in New York, NY.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://www.wsw.com/webcast/rrshq15/bstc.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX(TM) product in Europe.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
3. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
4. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
5. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
6. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
7. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
8. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
9. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
10. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
11. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... 20, 2017 , ... Husson University will be celebrating students ... of knowledge during its Eighth Annual Research and Scholarship Day on ... During the event, undergraduates, graduate students, and faculty members from all of the ...
(Date:4/20/2017)... ... 2017 , ... Energetiq Technology , a world leader ... Executive Officer (CEO) Debbie Gustafson has been appointed to the SEMI North America ... the electronics manufacturing supply chain. The mission of the SEMI NAAB is to ...
(Date:4/20/2017)... AMSTERDAM , April 20, 2017 Dutch philosopher Koert ... of ,Next Nature, at the University of Technology in Eindhoven - has ... In this letter, he calls on humanity to avoid becoming a slave and ... race. ... Dutch philosopher Koert van Mensvoort – founder of ...
(Date:4/19/2017)... ... April 18, 2017 , ... The ... a key device for generating monodisperse droplets of known diameters for research applications ... generating monodisperse solid particles by drying monodisperse droplets. , The VOAG requires ...
Breaking Biology Technology:
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):